EQRx, a company committed to developing and delivering important new medicines at lower prices, announced that its partner, Hansoh Pharmaceuticals, has disclosed topline results of its Phase III study of epidermal growth factor receptor (EGFR) inhibitor, aumolertinib, in the first-line setting.
